Abstract 841P
Background
Although several clinical parameters-based prediction indexes of extra-nodal natural killer/T-cell lymphoma (ENKTL) are proposed, these indexes include none of pathological index and had insufficient accuracy. A superior clinically feasible prediction index for ENKTL in the modern chemotherapy era is warranted.
Methods
600 ENKTL patients receiving non-anthracycline based therapy from Sun Yat-sen University Cancer Center were subdivided into training and internal validation datasets. An external validation dataset included 191 patients from West China Hospital was enrolled. Ki67 proliferative index and 14 pretreatment clinical parameters were tested against overall survival (OS) and progression-free survival (PFS). A prediction model was constructed and validated.
Results
Factors independently associated with inferior OS were as follows: Ki67 ≥ 70%; age > 60 years; ECOG PS ≥ 2; B symptoms; stage-III/-IV disease and detectable EBV-DNA copy number. Each of these six factors contributed one point to a prediction model that stratified patients into four risk groups: 0-1 point, low-risk; 2 points, intermediate-risk;3 points, intermediate high-risk; 4-6 points, high-risk. In the training dataset, the 5-year OS rates were 91%, 75%, 65% and 26% for the low-, intermediate-, intermediate high- and high-risk group, respectively (P < 0.001). The 5-year PFS rates were 79%, 62%, 48% and 15%, respectively (P < 0001). The time-dependent area under the receiver-operator characteristic (AUROC) curve and Harrell’s C-statistic of Ki67-revised Risk Index (KRI) for OS and PFS prediction demonstrated a better performance than that of the international prognostic index (IPI), Korean prognostic index (KPI), prognostic index of natural killer lymphoma (PINK) and nomogram-revised risk index (NRI). Concordant results were successfully validated in both internal and external validation datasets.
Conclusions
KRI is a new promising prediction index to risk-stratify patients with ENKTL receiving non-anthracycline based therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18